Methods of diagnosing prostate cancer through the detection of the presence or absence of Pax 2 mRNA

Patent Citations (10)

Non-Patent Literature (58)

• Gray et al. Cancer Research 55, 4800-4803, Nov. 1, 1995.*Applicant
• Adams, et at., “Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testes,” Genes & Development 6:1589-1607 (1992).Applicant
• Balaguer, et at., “Quantification of DNA sequences obtained by polymerase chain reaction using a bioluminescent adsorbent,” Analytical Biochemistry 195:105-110 (1991).Applicant
• Bernasconi, et al., “Induction of apoptosis in rhabdomyosarcoma cells through down-regualtion of PAX proteins,” Proc Natl Acad Sci USA 93:13164-69 (1996).Applicant
• Bischoff, et al., “An adventure mutant that replicates selectively in p53-deficient human tumor cells,” Science 274:373-376 (1996).Applicant
• Brawer, “Prostate Specific Antigen,” Acta Oncol. 30:161-168 (1991).Applicant
• Brothman, et al., “Frequency and pattern of karyotypic abnormalities in human prostate cancer,” Cancer Research 50:3795-3803 (1990).Applicant
• Busslinger, at al., “The role of BSAP (Pax-5) in B-cell development.” Current Opinion in Genetics and Development 5:595-601 (1995).Applicant
• Cancer Statistics: Registrations Engalnd and Wales OPCS MWI No. 22, Her Majesty's Stationery Office (1994).Applicant
• Cannon-Albright & Eeles, “Progress in prostate cancer,” Nature Genetics 9:336-338 (1995).Applicant
• Chamberlain, et al., “Report prepared for the health technology assessment panel of the NHS execution on the diagnosis, management, treatment and costs of prostate cancer an England and Wales,” British Journal of Urology 79(Suppl.3):1-32 (1997).Applicant
• Chan, et al., “Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study,” Science 279:563-566 (1998).Applicant
• Compton, Nucleic acid sequence-based amplification, Nature 350:91-92 (1991).Applicant
• Cotten, et al., “High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome-disruption activity of detective or chemically inactivated adenovirus particles,” Proc Natl Acad Sci USA 89:6094-6098 (1992).Applicant
• Culver, et al.. “In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors,” Science 256:1550-1552 (1992).Applicant
• Curiel, “Adenovirus facilitation of molecular conjugate-mediated gene transfer,” Prog Med Virol 40:1-18 (1993).Applicant
• Dicesare, et al., “A high-sensitivity electrochemiluminescence-based detection system for automated PCR product quantitation,” BioTechniques 15:152-157 (1993).Applicant
• Dressler, et al., “Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities,” Nature 362:665-67 (1993).Applicant
• Dressler, et at., “Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system,” Development 109(4): 787-795 (1990).Applicant
• Future Oncology “Prostate Cancer-Part II: Diagnosis, Staging, Prognosis, Screening, and Novel Molecular Markers,” 3(12): 1998.Applicant
• Gann, et al., “A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer,” JAMA 273: 289-294 (1995).Applicant
• Gao, et al., “Diagnostic and prognostic markers for human prostate cancer,” The Prostate 31:264-281 (1997).Applicant
• Gao, et al., “High frequency of mutator phenotype in human prostatic adenocarcinoma,” Oncogene 9:2999-3003 (1994).Applicant
• Gleason, “Classification of prostatic carcinomas,” Cancer Chemother Rep. 50:125-128 (1966).Applicant
• Gnarra & Dressler, “Expression of Pax-2 in human renal cell carninoma and growth inhibition by antisense oligonucleotides,” Cancer Research 55(18):4092-8 (1995).Applicant
• Jacobs, at al., “Tharmal stability of oligonucleotide duplexes is sequence independent in tetraalkylammonium application to identifying recombinant DNA clones,” Nucl. Acids Res. 16:4367 (1988).Applicant
• Khoubehi, et al., “The expression of the PAX2 in human prostate cancer,” Am J Human Genetics 65(Suppl. 4):A132 (1999).Applicant
• Khoubehi, et al., “Expression of the developmental and oncogenic PAX2 gene in human prostate cancer,” J Urology 165(6.1): 2115-2120.Applicant
• Koontz, et al., “Mitomycin, for patients who have failed on thiotepa,” Urology 26(4 Suppl.):30-31 (1985).Applicant
• Kuriyama, et al., “A Potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector,” Cell Structure and Function 16:503-510 (1991).Applicant
• Ledley, “Nonviral gene therapy: The promise of genes as pharmaceutical products,” Human Gene Therapy 6:1129-1144 (1995).Applicant
• Li, et al., “PTEN, a putative Protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer,” Science 275:1943-1947 (1997).Applicant
• Lundwall, “Characterization of the gene for prostate-specific antigen, a human glandular kallikrein,” Biochem. Biophys. Res. Comm. 161(3): 1151-1159 (1989).Applicant
• Martin & Papahadjopoulos, et al., “Irreversible coupling of immunoglobulin fragments to preformed vesicles,” J Biol Chem 257:286-88 (1982).Applicant
• Massenkeil, et al., “P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, I7p, and 18q are confined to advanced prostate cancer,” Anticancer Res. 14(6B): 2785-2790 (1994).Applicant
• Maulbecker & Gruss, “The oncogenic potential of Pax genes,” EMBO JournaI 12(6): 2361-2367 (1993).Applicant
• Michael, et al., “Addition of a short peptide ligand to the adenovirus fiber protein,” Gene Therapy 2:660-668 (1982).Applicant
• Miller & Vile, “Targeted vectors for gene therapy,” FASEB Journal 9(2): 190-199 (1995).Applicant
• Mortality Statistics: Cause. England and Wales. OPCS DH2 19, Her Majesty's Stationary Office, 1993.Applicant
• Nassander, et at., “In vivo targeting of OV-TL 3 immunoliposomes to Ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice,” Cancer Research 52:646-653 (1992).Applicant
• Nihel, et al., “Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10,” Genes, Chromosomes & Cancer 14(2): 112-119 (1995).Applicant
• Phelps & Dressler, “Aberrant expression of Pax-2 in Danforth's short tail (Sd) mice,” Developmental Biology 157(1): 251-258 (1993).Applicant
• Pogrebniak, et al., “Targetted phototherapy with sensitizer-monoclonal antibody conjugate and light,” Surgical Oncology 2(1): 31-42, 1993.Applicant
• Riegman, et al., “Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene,” Biochem Biophys. Res. Comm. 159(1): 95-102 (1989).Applicant
• Ryan, et al., “Repression at Pax-2 by WT1 during normal kidney development,” Development 121: 867-875 (1995).Applicant
• Saiki, et al., “Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase,” Science 239:487-491 (1988).Applicant
• Sanyanusin, et al., “Fenomic structure of the human PAX2 gene,” Genomics 35(1): 258-261 (1996).Applicant
• Schäfer, et al., “Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes,” Nuc. Acids Res. 22(22): 4574-4582 (1994).Applicant
• Smith & Catalona, “Interexaminer variability of digital rectal examination in detecting prostate cancer,” Urology 45(1): 70-74 (1995).Applicant
• Steck, et al., “Indentification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers,” Nature Genetics 15: 356-363 (1997).Applicant
• Stuart & Gruss, “PAX genes: What's new in developmental biology and cancer?” Human Mol. Gen. 4: 1717-1720 (1995).Applicant
• Stuart, et al, “Loss of p53 funtion through PAX-mediated transcriptional repression,” EMBO Journal 14: 5638-5645 (1995).Applicant
• Stuart, et al., “Mammalian PAX genes,” Annu Rev. Genet. 27: 219-236 (1993).Applicant
• Stuart, et al., “PAX and HOX in Neoplasia,” Adv. Genet. 33: 255-274 (1995).Applicant
• Wagner, et al., “Transferrin—polycation conjugates as carriers for DNA uptake into cells,” Proc. Nat. Acad. Sci. USA 87: 3410-3414 (1990).Applicant
• Walker, et al., “Strand displacement amplification—an isothermal, in vitro DNA amplification technique,” Nuc. Acids. Res. 20(7): 1691-1696 (1992).Applicant
• Yarmush, et al., “Antibody targeted photolysis,” Crit. Rev. Therap. Drug Carrier Syst. 10(3): 197-252 (1993).Applicant
• Zenklusen, et al., “Loss of heterozygosity in human primary prostate carcinomas: A possible tumor suppressor gene at 7q31.1.” Cancer Res. 54: 6370-6373 (1994).Applicant